Abstract: An aqueous enteric coating composition including hydroxypropylmethylcellulose, acetate succinate, and a basic amino acid.

Abstract: Provided are hypromellose acetate succinates (HPMCAS) for use as a hot-melt extrusion carrier having a volume average particle size (D50) of from 70 to 300 as measured by dry laser diffraction and a loose bulk density of from 0.25 to 0.40 g/cm3; and a hot-melt extrusion composition comprising the HPMCAS and a drug. Also provided is a method for producing a hot-melt extrudate including the steps of: hot-melting the hot-melt extrusion composition at a hot-melt temperature equal to or higher than a melting temperature of the HPMCAS, or at a hot-melt temperature equal to or higher than a temperature at which both of the HPMCAS and the drug become melt; and extruding the hot-melted composition.

Abstract: A pharmaceutical composition including an extruded solid and one or more pharmaceuticals or nutraceuticals is provided. The extruded solid includes hydroxypropylmethylcellulose acetate succinate and isomalt.

Abstract: An aqueous enteric coating composition including hydroxypropylmethylcellulose, acetate succinate, and a basic amino acid.

Abstract: A coating composition is provided. The coating composition includes a wet-milled product obtained by applying a shear force to an aqueous suspension of low-substituted cellulose ether having a molar substitution of from 0.05 to 1.0 per anhydrous glucose unit. The aqueous suspension of low-substituted cellulose ether is obtained by suspending and dispersing the low-substituted cellulose ether in water and a short chain alcohol.

Abstract: Provided is a composition for hot melt extrusion including a drug and hypromellose acetate succinate (HPMCAS) having a hydroxypropoxy molar substitution of 0.40 or more and a mole ratio of an acetyl group to a succinyl group of less than 1.6. Further, provided is a method for producing a hot melt extrudate including the step of hot melt-extruding a composition for hot melt extrusion including a drug and hypromellose acetate succinate having a molar hydroxypropoxy substitution of 0.40 or more and a mole ratio of an acetyl group to a succinyl group of less than 1.6, at a hot melt temperature of not lower than a melting temperature of the hypromellose acetate succinate or of not lower than a temperature at which both the hypromellose acetate succinate and the drug are melted.

Abstract: There are provided a solution for spray drying having a high transmittance and markedly reduced generation of undissolved matter; and a method for producing a solid dispersion by using the solution for spray drying so that clogging with the undissolved matter is reduced and dissolution is improved. More specifically, there is provided a solution for spray drying comprising hypromellose acetate succinate (HPMCAS) having a hydroxypropoxy molar substitution of 0.40 or more, a solvent, and a drug. There is also provided a method for producing a solid dispersion comprising the step of removing the solvent from the spray drying solution.

Abstract: A pharmaceutical composition including an extruded solid and one or more pharmaceuticals or nutraceuticals is provided. The extruded solid includes hydroxypropylmethylcellulose acetate succinate and isomalt.

Abstract: Provided are a composition for hot-melt extrusion which can be hot-melt extruded at a temperature lower than a conventional temperature and therefore free of heat-induced deactivation of a drug; and a method for producing a hot-melt extrusion product which is simpler than a spray-drying method. More specifically, provided is a composition for hot-melt extrusion including a drug and hypromellose acetate succinate (HPMCAS) having a hydroxypropoxy molar substitution of 0.40 or more. Also provided is a method for producing a hot-melt extrusion product including a step of hot-melt extruding a composition for hot-melt extrusion including a drug and hypromellose acetate succinate having a hydroxypropoxy molar substitution of 0.40 or more at a hot-melt temperature of melting temperature of the hypromellose acetate succinate or higher, or at a hot-melt temperature equal to or higher than a temperature at which both the hypromellose acetate succinate and the drug become melted.

Abstract: An aqueous enteric coating composition including hydroxypropylmethylcellulose, acetate succinate, and a basic amino acid.

Abstract: There are provided a solution for spray drying having a high transmittance and markedly reduced generation of undissolved matter; and a method for producing a solid dispersion by using the solution for spray drying so that clogging with the undissolved matter is reduced and dissolution is improved. More specifically, there is provided a solution for spray drying comprising hypromellose acetate succinate (HPMCAS) having a hydroxypropoxy molar substitution of 0.40 or more, a solvent, and a drug. There is also provided a method for producing a solid dispersion comprising the step of removing the solvent from the spray drying solution.

Abstract: Provided is a composition for hot melt extrusion including a drug and hypromellose acetate succinate (HPMCAS) having a hydroxypropoxy molar substitution of 0.40 or more and a mole ratio of an acetyl group to a succinyl group of less than 1.6. Further, provided is a method for producing a hot melt extrudate including the step of hot melt-extruding a composition for hot melt extrusion including a drug and hypromellose acetate succinate having a molar hydroxypropoxy substitution of 0.40 or more and a mole ratio of an acetyl group to a succinyl group of less than 1.6, at a hot melt temperature of not lower than a melting temperature of the hypromellose acetate succinate or of not lower than a temperature at which both the hypromellose acetate succinate and the drug are melted.

Abstract: Provided are hypromellose acetate succinates (HPMCAS) for use as a hot-melt extrusion carrier having a volume average particle size (D50) of from 70 to 300 as measured by dry laser diffraction and a loose bulk density of from 0.25 to 0.40 g/cm3; and a hot-melt extrusion composition comprising the HPMCAS and a drug. Also provided is a method for producing a hot-melt extrudate including the steps of: hot-melting the hot-melt extrusion composition at a hot-melt temperature equal to or higher than a melting temperature of the HPMCAS, or at a hot-melt temperature equal to or higher than a temperature at which both of the HPMCAS and the drug become melt; and extruding the hot-melted composition.

Abstract: Provided are a composition for hot-melt extrusion which can be hot-melt extruded at a temperature lower than a conventional temperature and therefore free of heat-induced deactivation of a drug; and a method for producing a hot-melt extrusion product which is simpler than a spray-drying method. More specifically, provided is a composition for hot-melt extrusion including a drug and hypromellose acetate succinate (HPMCAS) having a hydroxypropoxy molar substitution of 0.40 or more. Also provided is a method for producing a hot-melt extrusion product including a step of hot-melt extruding a composition for hot-melt extrusion including a drug and hypromellose acetate succinate having a hydroxypropoxy molar substitution of 0.40 or more at a hot-melt temperature of melting temperature of the hypromellose acetate succinate or higher, or at a hot-melt temperature equal to or higher than a temperature at which both the hypromellose acetate succinate and the drug become melted.

Abstract: The present invention provides solid preparations having two or more colors or a pattern of two or more different colors which can solve the problems of the prior art including the complexity of production processes and the low strength of solid preparations. Specifically, an object of the present invention is to provide solid preparations coated with a continuous film coating layer having two or more different colors or a pattern of two or more different colors which preparations are obtained by irradiating a part of the film coating layer containing one or more colorants with light, a process for the preparation of such solid preparations, and a film coating agent therefor.

Abstract: Fibers are modified by applying a solution of a low substituted cellulose ether having a molar degree of substitution with alkyl and/or hydroxyalkyl groups in the range of 0.05 to 1.0 in an aqueous alkali solution to fibers, and causing the solution borne on fibers to coagulate. The method achieves satisfactory fiber modifications with respect to antistatic property, moisture absorption and shrink resistance without a cumbersome step of dissolution while ensuring safety.

Abstract: In a paper/film composite structure, the film is made of a low substituted cellulose ether having a molar degree of substitution with alkyl and/or hydroxyalkyl groups in the range of 0.05 to 1.3. The paper/film composite structure can be delivered to the waste paper recycling process without previously removing the film portion. The strength of film is increased without adding to the manufacturing cost. The paper/film composite structure is inexpensive and eliminates the risk of film rupture during the working, transporting and use stages.

Abstract: Provided is a method for determining the absolute molecular weight and molecular weight distribution of low-substituted hydroxypropyl cellulose by using the light scattering method. More specifically, provided is a method for determining the absolute molecular weight and molecular weight distribution of low-substituted hydroxypropyl cellulose comprising steps of carbanilating a portion or all of the hydroxyl groups of the low-substituted hydroxypropyl cellulose, dissolving the carbanilated cellulose in a solvent to prepare a sample solution, and analyzing the resulting sample solution by subjecting it to gel permeation chromatography coupled with light scattering with a solvent identical or similar in kind to the solvent as a mobile phase.

Abstract: Provided is a cellulose polymer having a water retention property, and good feeling upon use when applied to the skin and being suitably used as a carrier. More specifically, provided is a low-substituted cellulose ether powder comprising primary particles wherein at least 95% by weight of the primary particles have an aspect ratio of 1.0 to 1.5. Also provided is a production process of a low-substituted cellulose ether powder having a molar substitution degree of 0.05 to 1.0, comprising, during or after the addition of an acid to an alkali solution of low-substituted cellulose ether to neutralize the solution, triturating a resulting mixture; and spray-drying a resulting dispersion. Further provided is a production process of a low-substituted cellulose ether powder having a molar substitution degree of 0.05 to 1.0, comprising shear-triturating a low-substituted cellulose ether powder in water so as to swell-disperse the powder and spray-drying a resulting dispersion.

Abstract: Fibers are modified by applying a solution of a low substituted cellulose ether having a molar degree of substitution with alkyl and/or hydroxyalkyl groups in the range of 0.05 to 1.0 in an aqueous alkali solution to fibers, and causing the solution borne on fibers to coagulate. The method achieves satisfactory fiber modifications with respect to antistatic property, moisture absorption and shrink resistance without a cumbersome step of dissolution while ensuring safety.